AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Vasomotor Symptoms of Menopause Pipeline Insights, 2019 Report - ResearchAndMarkets.com

April 9, 2019

DUBLIN--(BUSINESS WIRE)--Apr 9, 2019--The “Vasomotor Symptoms of Menopause - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vasomotor Symptoms of Menopause development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Vasomotor Symptoms of Menopause pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for the Vasomotor Symptoms of Menopause
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vasomotor Symptoms of Menopause
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vasomotor Symptoms of Menopause
  • The report also covers the dormant and discontinued pipeline projects related to the Vasomotor Symptoms of Menopause

Key Topics Covered:

1. Report Introduction

2. Vasomotor Symptoms of Menopause Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Vasomotor Symptoms of Menopause

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • Endoceutics
  • Therapeutics MD
  • Nerre Therapeutics Ltd.
  • Radius Health Inc.
  • Pherin Pharmaceuticals Inc.
  • Mithra Pharmaceuticals.
  • Euroscreen S.A
  • Yung Shin Pharmaceutical
  • Ausio Pharmaceuticals
  • Millendo Therapeutics Inc.
  • MenoGeniX Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Fervent Pharmaceuticals
  • QUE Oncology
  • Hibernaid Inc.
  • Eaton Scientific Systems

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ox12pi

View source version on businesswire.com:https://www.businesswire.com/news/home/20190409005625/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Women’s Health,Sexual and Reproductive Health Drugs

KEYWORD:

INDUSTRY KEYWORD: WOMEN HEALTH PHARMACEUTICAL CONSUMER

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/09/2019 08:58 AM/DISC: 04/09/2019 08:58 AM

http://www.businesswire.com/news/home/20190409005625/en